Tumor cell senescence in cancer treatment

Cancer Research

Volumn 63, Issue 11, 2003, Pages 2705-2715

  Roninson, Igor B ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BROXURIDINE; CYCLIN DEPENDENT KINASE INHIBITOR; DOXORUBICIN; PROTEIN P21; RETINOID;

CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER THERAPY; CELL AGING; CELL PROLIFERATION; CELL SECRETION; GENE EXPRESSION; GROWTH REGULATION; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; REGULATORY MECHANISM; REVIEW; STRESS; TELOMERE; TUMOR CELL; TUMOR PROMOTION;

ANIMALS; CELL AGING; HUMANS; NEOPLASMS;

EID: 0038277105     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Campisi, J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol., 11: S27-S31, 2001.
2. Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., and Pereira-Smith, O. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA, 92: 9363-9367, 1995.
3. Kurz, D. J., Decary, S., Hong, Y., and Erusalimsky, J. D. Senescence-associated β-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J. Cell Sci., 113: 3613-3622, 2000.
4. Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc. Natl. Acad. Sci. USA, 97: 4291-4296, 2000.
5. Krtolica, A., Parrinello, S., Lockett, S., Desprez, P. Y., and Campisi, J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl. Acad. Sci. USA, 98: 12072-12077, 2001.
6. Hayflick, L., and Moorhead, P. S. The serial cultivation of human diploid cell strains. Exp. Cell Res., 37: 585-621, 1961.
7. Mathon, N. F., and Lloyd, A. C. Cell senescence and cancer. Nat. Rev. Cancer, 1: 203-213, 2001.
8. Vaziri, H., West, M. D., Allsopp, R. C., Davison, T. S., Wu, Y. S., Arrowsmith, C. H., Poirier, G. G., and Benchimol, S. ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the posttranslational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO J., 16: 6018-6033, 1997.
9. von Zglinicki, T. Telomeres and replicative senescence: Is it only length that counts? Cancer Lett., 168: 111-116, 2001.
10. 1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev., 8: 2540-2551, 1994.
11. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., and Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell, 88: 593-602, 1997.
12. Zhu, J., Woods, D., McMahon, M., and Bishop, J. M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev., 12: 2997-3007, 1998.
13. Zhang, Y., Xiong, Y., and Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92: 725-734, 1998.
14. Pearson, M., Carbone, R., Sebastiani, C., Cioce, M., Fagioli, M., Saito, S., Higashimoto, Y., Appella, E., Minucci, S., Pandolfi, P. P., and Pelicci, P. G. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (Lond.), 406: 207-210, 2000.
15. Ferbeyre, G., de Stanchina, E., Querido, E., Baptiste, N., Prives, C., and Lowe, S. W. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev., 14: 2015-2027, 2000.
16. Dotto, G. P. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim. Biophys. Acta, 1471: M43-M56, 2000.
17. Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., and Smith, J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res., 211: 90-98, 1994.
18. Alcorta, D. A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., and Barrett, J. C. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. USA, 93: 13742-13747, 1996.
19. Stein, G. H., Drullinger, L. F., Soulard, A., and Dulic, V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol. Cell. Biol., 19: 2109-2117, 1999.
20. Ohtani, N., Zebedee, Z., Huot, T. J., Stinson, J. A., Sugimoto, M., Ohashi, Y., Sharrocks, A. D., Peters, G., and Hara, E. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature (Lond.), 409:1067-1070, 2001.
21. Wang, W., Wu, J., Zhang, Z., and Tong, T. Characterization of regulatory elements on the promoter region of p16(INK4a) that contribute to overexpression of p16 in senescent fibroblasts. J. Biol. Chem., 276: 48655-48661, 2001.
22. Bringold, F., and Serrano, M. Tumor suppressors and oncogenes in cellular senescence. Exp. Gerontol., 35: 317-329, 2000.
23. Munro, J., Steeghs, K., Morrison, V., Ireland, H., and Parkinson, E. K. Human fibroblast replicative senescence can occur in the absence of extensive cell division and short telomeres. Oncogene, 20: 3541-3552, 2001.
24. Malumbres, M., Perez, d. C., I, Hernandez, M. I., Jimenez, M., Corral, T., and Pellicer, A. Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b). Mol. Cell. Biol., 20: 2915-2925, 2000.
25. Rudolph, K. L., Chang, S., Lee, H. W., Blasco, M., Gottlieb, G. J., Greider, C., and DePinho, R. A. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell, 96: 701-712, 1999.
26. Morales, C. P., Holt, S. E., Ouellette, M., Kaur, K. J., Yan, Y., Wilson, K. S., White, M. A., Wright, W. E., and Shay, J. W. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat. Genet., 21: 115-118, 1999.
27. Tominaga, K., Olgun, A., Smith, J. R., and Pereira-Smith, O. M. Genetics of cellular senescence. Mech. Ageing Dev., 123: 927-936, 2002.
28. Bertram, M. J., Berube, N. G., Hang-Swanson, X., Ran, Q., Leung, J. K., Bryce, S., Spurgers, K., Bick, R. J., Baldini, A., Ning, Y., Clark, L. J., Parkinson, E. K., Barrett, J. C., Smith, J. R., and Pereira-Smith, O. M. Identification of a gene that reverses the immortal phenotype of a subset of cells and is a member of a novel family of transcription factor-like genes. Mol. Cell. Biol., 19: 1479-1485, 1999.
29. Alexander, K., and Hinds, P. W. Requirement for p27(KIP1) in retinoblastoma protein-mediated senescence. Mol. Cell. Biol., 21: 3616-3631, 2001.
30. Sugrue, M. M., Shin, D. Y., Lee, S. W., and Aaronson, S. A. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc. Natl. Acad. Sci. USA, 94: 9648-9653, 1997.
31. waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene, 18: 4808-4818, 1999.
32. Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene, 18: 2789-2797, 1999.
33. Dai, C. Y., and Enders, G. H. p16 INK4a can initiate an autonomous senescence program. Oncogene, 19: 1613-1622, 2000.
34. Waf1/Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells. Oncogene, 19: 2165-2170, 2000.
35. Hahn, W. C., Stewart, S. A., Brooks, M. W., York, S. G., Eaton, E., Kurachi, A., Beijersbergen, R. L., Knoll, J. H., Meyerson, M., and Weinberg, R. A. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med., 5: 1164-1170, 1999.
36. Stewart, S. A., Hahn, W. C., O'Connor, B. F., Banner, E. N., Lundberg, A. S., Modha, P., Mizuno, H., Brooks, M. W., Fleming, M., Zimonjic, D. B., Popescu, N. C., and Weinberg, R. A. Telomerase contributes to tumorigenesis by a telomere length- independent mechanism. Proc. Natl. Acad. Sci. USA, 99: 12606-12611, 2002.
37. Goodwin, E. C., Yang, E., Lee, C. J., Lee, H. W., DiMaio, D., and Hwang, E. S. Rapid induction of senescence in human cervical carcinoma cells. Proc. Natl. Acad Sci. USA, 97: 10978-10983, 2000.
38. Wells, S. I., Francis, D. A., Karpova, A. Y., Dowhanick, J. J., Benson, J. D., and Howley, P. M. Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21(CIP)-dependent pathways. EMBO J., 5762-5771, 2000.
39. Goodwin, E. C., and DiMaio, D. Induced senescence in HeLa cervical carcinoma cells containing elevated telomerase activity and extended telomeres. Cell Growth Differ., 12: 525-534, 2001.
40. Chang, B. D., Broude, E. V., Dokmanovic, M., Zhu, H., Ruth, A., Xuan, Y., Kandel, E. S., Lausch, E., Christov, K., and Roninson, I. B. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res., 59: 3761-3767, 1999.
41. Wang, X., Wong, S. C., Pan, J., Tsao, S. W., Fung, K. H., Kwong, D. L., Sham, J. S., and Nicholls, J. M. Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Res., 58: 5019-5022, 1998.
42. Park, J. I., Jeong, J. S., Han, J. Y., Kim, D. I., Gao, Y. H., Park, S. C., Rodgers, G. P., and Kim, I. H. Hydroxyurea induces a senescence-like change of K562 human erythroleukemia cell. J. Cancer Res. Clin. Oncol., 126: 455-460, 2000.
43. Haq, R., Brenton, J. D., Takahashi, M., Finan, D., Rottapel, R., and Zanke, B. Constitutive p38HOG mitogen-activated protein kinase activation induces permanent cell cycle arrest and senescence. Cancer Res., 62: 5076-5082, 2002.
44. te Poele, R. H., Okorokov, A. L., Jardine, L., Cummings, J., and Joel, S. P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res., 62: 1876-1883, 2002.
45. Elmore, L. W., Rehder, C. W., Di, X., McChesney, P. A., Jackson-Cook, C. K., Gewirtz, D. A., and Holt, S. E. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J. Biol. Chem., 277: 35509-35515, 2002.
46. Han, Z., Wei, W., Dunaway, S., Darnowski, J. W., Calabresi, P., Sedivy, J., Hendrickson, E. A., Balan, K. V., Pantazis, P., and Wyche, J. H. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J. Biol. Chem., 277: 17154-17160, 2002.
47. Michishita, E., Nakabayashi, K., Suzuki, T., Kaul, S. C., Ogino, H., Fujii, M., Mitsui, Y., and Ayusawa, D. 5-Bromodeoxyuridine induces senescence-like phenomena in mammalian cells regardless of cell type or species. J. Biochem. (Tokyo), 126: 1052-1059, 1999.
48. Suzuki, T., Minagawa, S., Michishita, E., Ogino, H., Fujii, M., Mitsui, Y., and Ayusawa, D. Induction of senescence-associated genes by 5-bromodeoxyuridine in HeLa cells. Exp. Gerontol., 36: 465-474, 2001.
49. Chang, B. D., Swift, M. E., Shen, M., Fang, J., Broude, E. V., and Roninson, I. B. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic drug. Proc. Natl. Acad. Sci. USA, 99: 389-394, 2002.
50. Horan, P. K., and Slezak, S. E. Stable cell membrane labelling. Nature (Lond.), 340: 167-168, 1989.
51. Ruth, A. C., and Roninson, I. B. Effects of the multidrug transporter P-glycoprotein on cellular responses to ionizing radiation. Cancer Res., 60: 2576-2578, 2000.
52. Levenson, V. V., Lausch, E., Kirschling, D. J., Broude, E. V., Davidovich, I. A., Libants, S., Fedosova, V., and Roninson, I. B. A combination of genetic suppressor elements produces resistance to drugs inhibiting DNA replication. Somat. Cell Mol. Genet., 25: 9-26, 1999.
53. Katakura, Y., Nakata, E., Miura, T., and Shirahata, S. Transforming growth factor β triggers two independent-senescence programs in cancer cells. Biochem. Biophys. Res. Commun., 255: 110-115, 1999.
54. Terao, Y., Nishida, J., Horiuchi, S., Rong, F., Ueoka, Y., Matsuda, T., Kato, H., Furugen, Y., Yoshida, K., Kato, K., and Wake, N. Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. Int. J. Cancer, 94: 257-267, 2001.
55. Roninson, I. B., and Dokmanovic, M. Induction of senescence-associated growth inhibitors in the tumor-suppressive function of retinoids. J. Cell Biochem., 88: 83-94, 2003.
56. Dokmanovic, M., Chang, B. D., Fang, J., and Roninson, I. B. Retinoid-induced growth arrest of breast carcinoma cells involves co-activation of multiple growthinhibitory genes. Cancer Biol. Ther., 1: 24-27, 2002.
57. Wainwright, L. J., Lasorella, A., and Iavarone, A. Distinct mechanisms of cell cycle arrest control the decision between differentiation and senescence in human neuroblastoma cells. Proc. Natl. Acad. Sci. USA, 98: 9396-9400, 2001.
58. Zhu, W. Y., Jones, C. S., Kiss, A., Matsukuma, K., Amin, S., and De Luca, L. M. Retinoic acid inhibition of cell cycle progression in MCF-7 human breast cancer cells. Exp. Cell Res., 234: 293-299, 1997.
59. Roninson, I. B., Broude, E. V., and Chang, B. D. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist. Updat., 4: 303-313, 2001.
60. Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., and Lowe, S. W. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell, 109: 335-346, 2002.
61. Lock, R. B., and Stribinskiene, L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res., 56: 4006-4012, 1996.
62. Zhu, H., Chang, B. D., Uchiumi, T., and Roninson, I. B. Identification of promoter elements responsible for transcriptional inhibition of polo-like kinase I and topoisomerase IIα genes by p21(WAF1/CIP1/SDI1). Cell Cycle, 1: 59-66, 2002.
63. Komarova, E. A., Diatchenko, L., Rokhlin, O. W., Hill, J. E., Wang, Z. J., Krivokrysenko, V. I., Feinstein, E., and Gudkov, A. V. Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53. Oncogene, 17: 1089-1096, 1998.
64. Adler, M. J., Coronel, C., Shelton, E., Seegmiller, J. E., and Dewji, N. N. Increased gene expression of Alzheimer disease beta-amyloid precursor protein in senescent cultured fibroblasts. Proc. Natl. Acad. Sci. USA, 88: 16-20, 1991.
65. Elenbaas, B., and Weinberg, R. A. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res., 264: 169-184, 2001.
66. Paradis, V., Youssef, N., Dargere, D., Ba, N., Bonvoust, F., Deschatrette, J., and Bedossa, P. Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. Hum. Pathol., 32: 327-332, 2001.
67. Choi, J., Shendrik, I., Peacocke, M., Peehl, D., Buttyan, R., Ikeguchi, E. F., Katz, A. E., and Benson, M. C. Expression of senescence-associated β-galactosidase in enlarged prostates from men with benign prostatic hyperplasia. Urology, 56: 160-166, 2000.
68. Saitoh, T., Sundsmo, M., Roch, J. M., Kimura, N., Cole, G., Schubert, D., Oltersdoff, T., and Schenk, D. B. Secreted form of amyloid β protein precursor is involved in the growth regulation of fibroblasts. Cell, 58: 615-622, 1989.
69. WAF1/CIP1/SDI1, changes in the expression of p21-regulated genes, and a senescence-like phenotype. Cancer Res., 61: 7754-7762, 2001.
70. Migliaccio, E., Giorgio, M., Mele, S., Pelicci, G., Reboldi, P., Pandolfi, P. P., Lanfrancone, L., and Pelicci, P. G. The p66shc adaptor protein controls oxidative stress response and life span in mammals [see comments]. Nature (Lond.), 402: 309-313, 1999.
71. Roninson, I. B. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett., 179: 1-14, 2002.
72. Perkins, N. D., Felzien, L. K., Betts, J. C., Leung, K., Beach, D. H., and Nabel, G. J. Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science (Wash. DC), 275: 523-527, 1997.
73. Snowden, A. W., Anderson, L. A., Webster, G. A., and Perkins, N. D. A novel transcriptional repression domain mediates p21(WAF1/CIP1) induction of p300 transactivation. Mol. Cell Biol., 20: 2676-2686, 2000.
74. Gregory, D. J., Garcia-Wilson, E., Poole, J. C., Snowden, A. W., Roninson, I. B., and Perkins, N. D. Induction of transcription through the p300 CRD1 motif by p21(WAF1/CIP1) is core promoter specific and cyclin dependent kinase independent. Cell Cycle, 1: 343-350, 2002.
75. Ravi, R. K., McMahon, M., Yangang, Z., Williams, J. R., Dillehay, L. E., Nelkin, B. D., and Mabry, M. Raf-1-induced cell cycle arrest in LNCaP human prostate cancer cells. J. Cell Biochem., 72: 458-469, 1999.
76. Cox, J. D., and Kline, R. W. Do prostatic biopsies 12 months or more after external irradiation for adenocarcinoma, Stage III, predict long-term survival? Int. J. Radiat. Oncol. Biol. Phys., 9: 299-303, 1983.
77. Bataini, J. P., Belloir, C., Mazabraud, A., Pilleron, J. P., Cartigny, A., Jaulerry, C., and Ghossein, N. A. Desmoid tumors in adults: the role of radiotherapy in their management. Am. J. Surg., 155: 754-760, 1988.
78. Gu, K., Mes-Masson, A. M., Gauthier, J., and Saad, F. Analysis of the p16 tumor suppressor gene in early-stage prostate cancer. Mol. Carcinog., 21: 164-170, 1998.
79. Lee, C. T., Capodieci, P., Osman, I., Fazzari, M., Ferrara, J., Scher, H. I., and Cordon-Cardo, C. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin. Cancer Res., 5: 977-983, 1999.
80. Halvorsen, O. J., Hostmark, J., Haukaas, S., Hoisaeter, P. A., and Akslen, L. A. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer (Phila.), 88: 416-424, 2000.
81. Henshall, S. M., Quinn, D. I., Lee, C. S., Head, D. R., Golovsky, D., Brenner, P. C., Delprado, W., Stricker, P. D., Grygiel, J. J., and Sutherland, R. L. Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin. Cancer Res., 7: 544-550, 2001.
82. Hui, R., Macmillan, R. D., Kenny, F. S., Musgrove, E. A., Blamey, R. W., Nicholson, R. I., Robertson, J. F., and Sutherland, R. L. INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin. Cancer Res., 6: 2777-2787, 2000.
83. Milde-Langosch, K., Bamberger, A. M., Rieck, G., Kelp, B., and Loning, T. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res. Treat., 67: 61-70, 2001.
84. Han, S., Ahn, S. H., Park, K., Bae, B. N., Kim, K. H., Kim, H. J., Kim, Y. D., and Kim, H. Y. P16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy. Breast Cancer Res. Treat., 70: 205-212, 2001.
85. Osman, I., Drobnjak, M., Fazzari, M., Ferrara, J., Scher, H. I., and Cordon-Cardo, C. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin. Cancer Res., 5: 2082-2088, 1999.
86. Aaltomaa, S., Lipponen, P., Eskelinen, M., Ala-Opas, M., and Kosma, V. M. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate, 39: 8-15, 1999.
87. Baretton, G. B., Klenk, U., Diebold, J., Schmeller, N., and Lohrs, U. Proliferationand apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br. J. Cancer, 80: 546-555, 1999.
88. Sarkar, F. H., Li, Y., Sakr, W. A., Grignon, D. J., Madan, S. S., Wood, D. P., Jr., and Adsay. V. Relationship of p21(WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa). Prostate, 40: 256-260, 1999.
89. Lacombe, L., Maillette, A., Meyer, F., Veilleux, C., Moore, L., and Fradet, Y. Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. Int. J. Cancer, 95: 135-139, 2001.
90. Fizazi, K., Martinez, L. A., Sikes, C. R., Johnston, D. A., Stephens, L. C., McDonnell, T. J., Logothetis, C. J., Trapman, J., Pisters, L. L., Ordonez, N. G., Troncoso, P., and Navone, N. M. The association of p21(WAF-1/CIP1) with progression to androgen-independent prostate cancer. Clin. Cancer Res., 8: 775-781, 2002.
91. Matsushima, H., Sasaki, T., Goto, T., Hosaka, Y., Homma, Y., Kitamura, T., Kawabe, K., Sakamoto, A., Murakami, T., and Machinami, R. Immunohistochemical study of p21WAF1 and p53 proteins in prostatic cancer and their prognostic significance. Hum. Pathol., 29: 778-783, 1998.
92. Cheng, L., Lloyd, R. V., Weaver, A. L., Pisansky, T. M., Cheville, J. C., Ramnani, D. M., Leibovich, B. C., Blute, M. L., Zincke, H., and Bostwick, D. G. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin. Cancer Res., 6: 1896-1899, 2000.
93. Shariat, S. F., Lamb, D. J., Kattan, M. W., Nguyen, C., Kim, J., Beck, J., Wheeler, T. M., and Slawin, K. M. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J. Clin. Oncol., 20: 833-841, 2002.
94. Chan, J. M., Stampfer, M. J., Ma, J., Gann, P., Gaziano, J. M., Pollak, M., and Giovannucci, E. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J. Natl. Cancer Inst. (Bethesda), 94: 1099-1106, 2002.
95. Gupta, S., Hastak, K., Ahmad, N., Lewin, J. S., and Mukhtar, H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc. Natl. Acad. Sci. USA, 98: 10350-10355, 2001.
96. Schwarze, S. R., DePrimo, S. E., Grabert, L. M., Fu, V. X., Brooks, J. D., and Jarrard, D. F. Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J. Biol. Chem., 277: 14877-14883, 2002.
97. Zi, X., Zhang, J., Agarwal, R., and Pollak, M. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgenindependent prostate cancer cells. Cancer Res., 60: 5617-5620, 2000.
98. Tsubaki. J., Hwa, V., Twigg, S. M., and Rosenfeld, R. G. Differential activation of the IGF binding protein-3 promoter by butyrate in prostate cancer cells. Endocrinology, 143: 1778-1788, 2002.
99. Lopez-Bermejo, A., Buckway, C. K., Devi, G. R., Hwa, V., Plymate, S. R., Oh, Y., and Rosenfeld, R. G. Characterization of insulin-like growth factor-binding proteinrelated proteins (IGFBP-rPs) 1, 2, and 3 in human prostate epithelial cells: potential roles for IGFBP-rP1 and 2 in senescence of the prostatic epithelium. Endocrinology, 141: 4072-4080, 2000.
100. 1 and cyclin A associated apoptosis. Oncogene, 21: 140-147, 2002.
101. Zou, Z., Gao, C., Nagaich, A. K., Connell, T., Saito, S., Moul, J. W., Seth, P., Appella, E., and Srivastava, S. p53 regulates the expression of the tumor suppressor gene maspin. J. Biol. Chem., 275: 6051-6054, 2000.
102. Machtens, S., Serth, J., Bokemeyer, C., Bathke, W., Minssen, A., Kollmannsberger, C., Hartmann, J., Knuchel, R., Kondo, M., Jonas, U., and Kuczyk, M. Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features. Int. J. Cancer, 95: 337-342, 2001.
103. Zou, Z., Zhang, W., Young, D., Gleave, M. G., Rennie, P., Connell, T., Connelly, R., Moul, J., Srivastava, S., and Sesterhenn, I. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of maspin expression by androgen ablation. Clin. Cancer Res., 8: 1172-1177, 2002.
104. Ling, Y. H., Zou, Y., and Perez-Soler, R. Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells. Anticancer Res., 20: 693-702, 2000.
105. Jung, M. S., Yun, J., Chae, H. D., Kim, J. M., Kim, S. C., Choi, T. S., and Shin, D. Y. p53 and its homologues, p63 and p73, induce a replicative senescence through inactivation of NF-Y transcription factor. Oncogene, 20: 5818-5825, 2001.
106. Xu, H. J., Zhou, Y., Ji, W., Perng, G. S., Kruzelock, R., Kong, C. T., Bast, R. C., Mills, G. B., Li, J., and Hu, S. X. Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene, 15: 2589-2596, 1997.
107. Wang, Y., Blandino, G., and Givol, D. Induced p21waf expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. Oncogene, 18: 2643-2649, 1999.
108. Kagawa, S., Fujiwara, T., Kadowaki, Y., Fukazawa, T., Sok-Joo, R., Roth, J. A., and Tanaka, N. Overexpression of the p21 sdi1 gene induces senescence-like state in human cancer cells: implication for senescence-directed molecular therapy for cancer. Cell Death Differ., 6: 765-772, 1999.
109. Uhrbom, L., Nister, M., and Westermark, B. Induction of senescence in human malignant glioma cells by p16INK4A. Oncogene, 15: 505-514, 1997.
110. Fuxe, J., Akusjarvi, G., Goike, H. M., Roos, G., Collins, V. P., and Pettersson, R. F. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A. Cell Growth Differ., 11: 373-384, 2000.
111. Tsugu, A., Sakai, K., Dirks, P. B., Jung, S., Weksberg, R., Fei, Y. L., Mondal, S., Ivanchuk, S., Ackerley, C., Hamel, P. A., and Rutka, J. T. Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence. Am. J. Pathol., 157: 919-932, 2000.
112. Wilson, H. M., Birnbaum, R. S., Poot, M., Quinn, L. S., and Swisshelm, K. Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. Cell Growth Differ., 13: 205-213, 2002.